SCM
NMRA icon

Sterling Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Sterling Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612 Buy
+360
New +$685 ﹤0.01% 3205
2025
Q2 		– Sell
-86
Closed -$86 – 3346
2025
Q1 		$86 Hold
86
– – ﹤0.01% 3153
2024
Q4 		$912 Hold
86
– – ﹤0.01% 2960
2024
Q3 		$1.14K Buy
+86
New +$1K ﹤0.01% 2461

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's NMRA Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 360 shares worth $612. The stake represents ﹤0.01% of the portfolio and ranks #3205 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in NMRA as recently as Q1 2025.

Sterling Capital Management first reported a position in NMRA in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.14K in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Sterling Capital Management held 360 shares of Neumora Therapeutics worth $612 as of Q2 2026.
  • Neumora Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3205 holding.
  • Sterling Capital Management first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Sterling Capital Management's Neumora Therapeutics position peaked at $1.14K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.